MA43960A - Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 - Google Patents
Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1Info
- Publication number
- MA43960A MA43960A MA043960A MA43960A MA43960A MA 43960 A MA43960 A MA 43960A MA 043960 A MA043960 A MA 043960A MA 43960 A MA43960 A MA 43960A MA 43960 A MA43960 A MA 43960A
- Authority
- MA
- Morocco
- Prior art keywords
- hiv
- inhibitors
- compounds
- modified triterpenoids
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
- C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/52—Ortho- or ortho- and peri-condensed systems containing five condensed rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- AIDS & HIV (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne des composés ayant des propriétés thérapeutiques et bioactives, leurs compositions pharmaceutiques et leurs procédés d'utilisation. L'invention concerne, en particulier, des dérivés de l'acide bétulinique ayant une activité antivirale unique, qui sont utilisés comme inhibiteurs de maturation du vih, tels que représentés par des composés de formule i : ces composés s'avèrent utiles dans le traitement du vih et du sida.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291298P | 2016-02-04 | 2016-02-04 | |
| PCT/IB2017/050568 WO2017134596A1 (fr) | 2016-02-04 | 2017-02-02 | Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA43960A true MA43960A (fr) | 2018-12-12 |
| MA43960B1 MA43960B1 (fr) | 2021-02-26 |
Family
ID=57995251
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053358A MA53358A (fr) | 2016-02-04 | 2017-02-02 | Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 |
| MA43960A MA43960B1 (fr) | 2016-02-04 | 2017-02-02 | Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053358A MA53358A (fr) | 2016-02-04 | 2017-02-02 | Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 |
Country Status (38)
| Country | Link |
|---|---|
| US (4) | US10421774B2 (fr) |
| EP (2) | EP3831839B1 (fr) |
| JP (1) | JP6735837B2 (fr) |
| KR (1) | KR20180105229A (fr) |
| CN (1) | CN109153700B (fr) |
| AR (1) | AR107512A1 (fr) |
| AU (1) | AU2017215529B2 (fr) |
| BR (1) | BR112018015629B1 (fr) |
| CA (1) | CA3013417C (fr) |
| CL (1) | CL2018002084A1 (fr) |
| CO (1) | CO2018008157A2 (fr) |
| CR (1) | CR20180387A (fr) |
| CY (1) | CY1124353T1 (fr) |
| DK (1) | DK3411381T3 (fr) |
| DO (1) | DOP2018000174A (fr) |
| EA (1) | EA036211B1 (fr) |
| ES (2) | ES2862325T3 (fr) |
| HK (1) | HK1256866A1 (fr) |
| HR (1) | HRP20210502T1 (fr) |
| HU (1) | HUE054337T2 (fr) |
| IL (1) | IL260741B (fr) |
| JO (1) | JOP20170029B1 (fr) |
| LT (1) | LT3411381T (fr) |
| MA (2) | MA53358A (fr) |
| MD (1) | MD3411381T2 (fr) |
| MX (1) | MX2018009514A (fr) |
| PE (1) | PE20181355A1 (fr) |
| PL (1) | PL3411381T3 (fr) |
| PT (1) | PT3411381T (fr) |
| RS (1) | RS61746B1 (fr) |
| RU (1) | RU2716502C2 (fr) |
| SG (1) | SG11201806388XA (fr) |
| SI (1) | SI3411381T1 (fr) |
| TW (1) | TWI719126B (fr) |
| UA (1) | UA123867C2 (fr) |
| UY (1) | UY37109A (fr) |
| WO (1) | WO2017134596A1 (fr) |
| ZA (1) | ZA201805044B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR107512A1 (es) * | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
| EP4321164A3 (fr) | 2018-04-24 | 2024-04-17 | ViiV Healthcare UK (No.5) Limited | Composés ayant une activité inhibitrice de la maturation du vih |
| TW202135815A (zh) | 2019-12-09 | 2021-10-01 | 美商 Ｖｉｉｖ 醫療保健公司 | 醫藥組合物 |
| WO2024089216A1 (fr) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Nouveaux composés hétéroaryl-carboxamides contenant du soufre |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5679828A (en) | 1995-06-05 | 1997-10-21 | Biotech Research Labs, Inc. | Betulinic acid and dihydrobetulinic acid derivatives and uses therefor |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US7365221B2 (en) | 2002-09-26 | 2008-04-29 | Panacos Pharmaceuticals, Inc. | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| GB0301227D0 (en) | 2003-01-20 | 2003-02-19 | Keen Group Ltd | Seating apparatus |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| US20050239748A1 (en) | 2004-03-17 | 2005-10-27 | Panacos Pharmaceuticals, Inc. | Pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid |
| TW200628161A (en) | 2004-11-12 | 2006-08-16 | Panacos Pharmaceuticals Inc | Novel betulin derivatives, preparation thereof and use thereof |
| WO2008115281A2 (fr) | 2006-10-16 | 2008-09-25 | Myriad Genetics, Inc. | Composés de traitement d'infections virales |
| JP2011511812A (ja) | 2008-02-14 | 2011-04-14 | バイロケム ファーマ インコーポレイテッド | 新規１７βルパン誘導体 |
| US9067966B2 (en) | 2009-07-14 | 2015-06-30 | Hetero Research Foundation, Hetero Drugs Ltd. | Lupeol-type triterpene derivatives as antivirals |
| FR2956034B1 (fr) | 2010-02-09 | 2012-02-10 | Thales Sa | Dispositif d'entrainement pour des joueurs de rugby |
| CA2801487C (fr) | 2010-06-04 | 2017-12-05 | Bristol-Myers Squibb Company | Derives d'acide betulinique modifies en c-3, utilises comme inhibiteurs de maturation du vih |
| US8802661B2 (en) | 2010-06-04 | 2014-08-12 | Bristol-Myers Squibb Company | C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors |
| DE102010017786A1 (de) | 2010-07-07 | 2012-01-12 | Continental Reifen Deutschland Gmbh | Elastomerprodukt, enthaltend ein linienförmiges, textiles Gebilde zur Verstärkung |
| RS54352B1 (en) | 2011-01-31 | 2016-02-29 | Bristol-Myers Squibb Company | C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV INVESTIGATION INHIBITORS |
| CA2826113C (fr) * | 2011-01-31 | 2018-09-04 | Bristol-Myers Squibb Company | Triterpenoides modifies en c-17 et c-3 presentant une activite inhibitrice de la maturation du vih |
| AU2012352129B2 (en) * | 2011-12-14 | 2016-02-04 | Glaxosmithkline Llc | Propenoate derivatives of betulin |
| US8906889B2 (en) | 2012-02-15 | 2014-12-09 | Bristol-Myers Squibb Company | C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity |
| US8889854B2 (en) | 2012-05-07 | 2014-11-18 | Bristol-Myers Squibb Company | C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity |
| EP2935240A1 (fr) | 2012-12-21 | 2015-10-28 | Epizyme, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| US9378035B2 (en) | 2012-12-28 | 2016-06-28 | Commvault Systems, Inc. | Systems and methods for repurposing virtual machines |
| EP2953960A1 (fr) * | 2013-02-06 | 2015-12-16 | Bristol-Myers Squibb Company | Triterpénoïdes modifiés en c-19 ayant une activité inhibant la maturation du vih |
| CN105102468A (zh) | 2013-02-25 | 2015-11-25 | 百时美施贵宝公司 | 用于治疗hiv的c-3烷基和烯基修饰的桦木酸衍生物 |
| CN104877015B (zh) * | 2014-02-28 | 2019-02-01 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种三萜-多肽缀合物、其药物组合物及用途 |
| CA2944778C (fr) | 2014-04-11 | 2022-06-14 | ViiV Healthcare UK (No.4) Limited | Triterpenes a activite d'inhibition de la maturation du vih |
| MA40886B1 (fr) | 2015-02-09 | 2020-03-31 | Hetero Research Foundation | Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih |
| AR107512A1 (es) * | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
| ES2907373T3 (es) | 2016-02-04 | 2022-04-25 | Takeda Pharmaceuticals Co | Compuesto de piperidina sustituida y uso de la misma |
-
2017
- 2017-02-01 AR ARP170100255A patent/AR107512A1/es unknown
- 2017-02-02 CA CA3013417A patent/CA3013417C/fr active Active
- 2017-02-02 MX MX2018009514A patent/MX2018009514A/es active IP Right Grant
- 2017-02-02 KR KR1020187025343A patent/KR20180105229A/ko not_active Application Discontinuation
- 2017-02-02 SG SG11201806388XA patent/SG11201806388XA/en unknown
- 2017-02-02 ES ES17704093T patent/ES2862325T3/es active Active
- 2017-02-02 RU RU2018130181A patent/RU2716502C2/ru active
- 2017-02-02 LT LTEP17704093.8T patent/LT3411381T/lt unknown
- 2017-02-02 PT PT177040938T patent/PT3411381T/pt unknown
- 2017-02-02 EP EP21152161.2A patent/EP3831839B1/fr active Active
- 2017-02-02 BR BR112018015629-9A patent/BR112018015629B1/pt active IP Right Grant
- 2017-02-02 PE PE2018001378A patent/PE20181355A1/es unknown
- 2017-02-02 EP EP17704093.8A patent/EP3411381B1/fr active Active
- 2017-02-02 EA EA201891649A patent/EA036211B1/ru unknown
- 2017-02-02 UY UY0001037109A patent/UY37109A/es not_active Application Discontinuation
- 2017-02-02 CR CR20180387A patent/CR20180387A/es unknown
- 2017-02-02 MA MA053358A patent/MA53358A/fr unknown
- 2017-02-02 RS RS20210450A patent/RS61746B1/sr unknown
- 2017-02-02 TW TW106103410A patent/TWI719126B/zh active
- 2017-02-02 ES ES21152161T patent/ES2957767T3/es active Active
- 2017-02-02 HU HUE17704093A patent/HUE054337T2/hu unknown
- 2017-02-02 AU AU2017215529A patent/AU2017215529B2/en active Active
- 2017-02-02 JO JOP/2017/0029A patent/JOP20170029B1/ar active
- 2017-02-02 CN CN201780018790.8A patent/CN109153700B/zh active Active
- 2017-02-02 WO PCT/IB2017/050568 patent/WO2017134596A1/fr active Application Filing
- 2017-02-02 JP JP2018540806A patent/JP6735837B2/ja active Active
- 2017-02-02 PL PL17704093T patent/PL3411381T3/pl unknown
- 2017-02-02 MD MDE20181181T patent/MD3411381T2/ro unknown
- 2017-02-02 SI SI201730647T patent/SI3411381T1/sl unknown
- 2017-02-02 US US16/071,925 patent/US10421774B2/en active Active
- 2017-02-02 MA MA43960A patent/MA43960B1/fr unknown
- 2017-02-02 DK DK17704093.8T patent/DK3411381T3/da active
- 2017-02-02 UA UAA201808249A patent/UA123867C2/uk unknown
-
2018
- 2018-07-23 IL IL260741A patent/IL260741B/en active IP Right Grant
- 2018-07-26 ZA ZA2018/05044A patent/ZA201805044B/en unknown
- 2018-07-30 DO DO2018000174A patent/DOP2018000174A/es unknown
- 2018-07-31 CO CONC2018/0008157A patent/CO2018008157A2/es unknown
- 2018-08-02 CL CL2018002084A patent/CL2018002084A1/es unknown
- 2018-12-12 HK HK18115964.0A patent/HK1256866A1/zh unknown
-
2019
- 2019-08-07 US US16/534,208 patent/US11084845B2/en active Active
-
2021
- 2021-03-29 HR HRP20210502TT patent/HRP20210502T1/hr unknown
- 2021-04-08 CY CY20211100303T patent/CY1124353T1/el unknown
- 2021-06-09 US US17/342,941 patent/US20210323997A1/en not_active Abandoned
-
2022
- 2022-12-16 US US18/083,037 patent/US20230295220A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34909B1 (fr) | Triterpénoïdes modifi2s en c-17 et c-3 presentant une activité inhibitrice de la maturation du vih | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA39985B1 (fr) | 1h-pyrrolo [2,3-c]pyridine -7(6h)-ones et pyrazolo[3,4-c]pyridine-7(6h)-ones en tant qu'inhibiteurs de protéines bet | |
| MA43960A (fr) | Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 | |
| MA53399B1 (fr) | Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
| MA35750B1 (fr) | Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c) | |
| MA34400B1 (fr) | Dérivés d'acide 2-quinolinyl-acétique en tant que composés antiviraux contre le vih | |
| MA44674B1 (fr) | Inhibiteurs de bromodomaine | |
| MA40523A (fr) | 2-(morpholin-4-yl)-1,7-naphthyridines | |
| MA38483A1 (fr) | Inhibiteurs de l'ido | |
| MA40886B1 (fr) | Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih | |
| MA40955A (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| MA34397B1 (fr) | Dérivés d'acide napht-2-ylacétique dans le traitement du sida | |
| MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
| MA39317A1 (fr) | Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe | |
| MA39374A1 (fr) | Triterpénoïdes présentant une activité d'inhibition de la maturation du vih, substitués en 3ème position par un cycle non aromatique portant un substituant halogénoalkyle | |
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA34170B1 (fr) | Inhibiteurs de transcriptase inverse non nucléosidiques | |
| MA41185B1 (fr) | Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc | |
| EA202192433A1 (ru) | Соединения, полезные в терапии вич | |
| MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
| MA38678A1 (fr) | Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués | |
| MA39750B1 (fr) | Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2 | |
| MA40149A1 (fr) | Dérivés de nucléoside 4'-vinyle substitués utiles en tant qu'inhibiteurs de la réplication due l'arn du virus respiratoire syncytial |